For investors looking for a systematic way to find high-growth stocks, the method in Louis Navellier's "The Little Book That Makes You Rich" presents a strong framework. The plan centers on eight basic rules meant to find companies showing better earnings momentum, faster sales, growing profitability, and sound financial condition. By sorting for these particular factors, investors try to build a portfolio of stocks set for major price gains. A recent filter using this plan has pointed to Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) as a candidate for more detailed review.
Fitting the "Little Book" Factors
Aurinia Pharmaceuticals seems to fit a number of Navellier's important growth filters, which are vital for finding companies with positive business momentum. The given data shows good agreement with the plan's main principles.
- Positive Earnings Revisions & Surprises: A key part of the method is finding companies where analyst forecasts are increasing, often because of steady better-than-expected results. Aurinia fits this with an 8.34% rise in next-quarter EPS forecasts over the past three months. More notably, the company has reported four straight positive earnings surprises, with an average beat of 30.6%. This habit of beating forecasts can lead to more estimate increases and investor attention.
- Strong Sales and Earnings Growth: The plan requires clear growth. Aurinia displays a 20.4% year-over-year rise in revenue and a large 28.8% growth in the newest quarter versus the same time last year. More notable is the earnings growth: EPS jumped 800% over the last year, with the most recent quarter showing a 2500% rise year-over-year. This shows strong operational leverage.
- Growing Profitability and Sound Cash Flow: Growing sales alone is insufficient; a company must also become more profitable. Aurinia’s operating margin has grown by a remarkable 380.6% over the past year. Also, its free cash flow—important for funding growth—has increased by about 207% year-over-year, showing a firming financial state.
- High Return on Equity (ROE): The last rule looks for efficient use of shareholder money. Aurinia’s ROE of 49.4% is very high, meaning the company is producing significant profit from the equity invested in the business.
Fundamental Condition and Valuation Setting
A wider view of Aurinia's financial profile, as shown in its detailed fundamental analysis report, gives more setting. The company has an overall fundamental rating of 6 out of 10. Its financial condition is a key strength, with a high solvency score, a strong Altman-Z score pointing to low bankruptcy risk, and a very workable debt level. Profitability measures are very good, including industry-leading margins and returns on assets and equity.
On valuation, the view is mixed. While Aurinia’s Price-to-Earnings (P/E) ratio of 17.5 seems high on an absolute basis, it is actually lower than almost 95% of its biotechnology industry peers. This implies the market may be pricing its fast growth at a relative discount compared to the sector. The main worry noted is a high PEG ratio, which means the stock’s price may already account for much of its future growth, with earnings forecast to increase at a more moderate rate ahead.
Investment Points
For investors using the "Little Book" plan, Aurinia offers a strong case study. It clearly shows the earnings momentum, sales speed-up, and margin growth the method looks for. The company’s shift to commercial-stage operations with its drug LUPKYNIS is appearing in the strong financial measures caught by the filter. Still, as with any growth investment, risks stay. The company’s future is closely linked to the commercial success and market reach of its main product, and the biotech field is naturally unstable. The current neutral long-term trend for the wider S&P 500, set against a positive short-term trend, also indicates a choosy market setting where fundamental strength is key.
The filter that found Aurinia Pharmaceuticals is built on a tested growth investing framework and can be a useful beginning for more study. You can review the present list of stocks passing this "Little Book" filter and change the factors to your own needs by visiting the screener here.
Disclaimer: This article is for information only and does not make up financial advice, a suggestion, or an offer or request to buy or sell any securities. The information shown is based on data supplied and should not be the only ground for an investment choice. Investors should do their own complete research and talk with a qualified financial advisor before making any investment decisions.
